Retension Pharmaceuticals Reports Q3 2026 Results, $5.9 Million Net Loss
Retension Pharmaceuticals reported a third-quarter 2026 net loss of $5.9 million, compared with $1.5 million a year earlier, as research and development costs increased during its Phase 2b trial. Cash and cash equivalents totaled $9.2 million at quarter-end, before the company’s October IPO. Retens…